HistoSonics, the company behind the revolutionary Edison® Histotripsy System, has announced a landmark $2.25 billion acquisition led by a consortium of major global investors including Bezos Expeditions, K5 Global, Wellington Management, and several others. The transaction, which is a management-led majority stake acquisition, marks a significant milestone in the company’s journey to scale its non-invasive tumor therapy globally and accelerate its entry into new clinical indications.
With a focus on expanding beyond its current applications in liver tumors, HistoSonics plans to develop histotripsy-based treatments for kidney, pancreas, and prostate conditions. The company envisions a future where histotripsy could be used for a wide range of clinical applications, treating both benign and malignant tumors across the body. CEO Mike Blue, who will continue to lead the company and serve as the new Chairman of the Board, emphasized the urgency of delivering better therapeutic alternatives to patients worldwide.
The Edison system, which received FDA De Novo clearance in October 2023, utilizes focused ultrasound energy to mechanically destroy and liquify targeted tissue—without incisions, heat, or radiation. This makes it a promising alternative to traditional invasive procedures and toxic therapies. Over 2,000 patients have been treated using Edison at more than 50 U.S. medical centers, and another 50 installations are planned by year-end. The system is also being evaluated in ongoing clinical trials for liver, kidney (HOPE4KIDNEY Trial), and pancreas tumors (GANNON Trial), showing strong momentum in research and adoption.
Investors backing this deal include a mix of new and existing partners such as Alpha JWC Ventures, Johnson & Johnson’s venture arm (JJDC), Alpha Wave Ventures, and several U.S. state investment boards. According to K5 Global, the investment reflects confidence in HistoSonics’ ability to transform tumor treatment globally, as the company continues to demonstrate strong clinical results and growing hospital demand.
With this new capital and strategic backing, HistoSonics is well-positioned to redefine the landscape of non-invasive tumor therapy, making histotripsy a potential standard of care in multiple disease areas around the world.
HistoSonics acquired in $2.25B deal to drive global growth of Edison® Histotripsy System.
Plans expansion into kidney, pancreas, and prostate tumor treatment.
Technology uses non-invasive focused ultrasound to liquify tumors with precision.
